to clinical settings
for better patient care
CorticoMetrics’ FDA 510(k)-cleared product, called THINQ™, is not currently offered for sale. It is indicated for clinical use by neurologists, radiologists and neuroradiologists in the post-acquisition quantitative analysis of MRI brain scans.
THINQ targets problems faced by radiologists and neurologists
CorticoMetrics’ FDA 510(k)-cleared product, called THINQ™, is not currently offered for sale.
AI-based software for advanced imaging
CorticoMetrics was formed in 2012 to commercialize neuroimaging analysis software developed at the Massachusetts General Hospital (MGH), known to researchers worldwide as FreeSurfer. It was co-founded by Dr. Bruce Fischl, the Director of the Laboratory for Computational Neuroimaging (home of FreeSurfer) and Mr. Nick Schmansky, formerly the lab’s Lead Software Engineer.